Drug Trial Radar · NCT02094443
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
Last checked: Nov 19, 2026Latest source record: Oct 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 2014
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination with ribavirin (RBV) during the first 12 weeks treatment in chronic hepatitis C genotype (GT)-2 and GT-3 patients who had previously failed interferon therapy or were intolerant or unable to take interferon.
Conditions
- Hepatitis C
- Liver Disease
Interventions
AlisporivirDrug
ALV 100 and 200 mg soft gel capsules administered orally
RibavirinDrug
RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hepatitis C Virus Ribonucleic Acid Viral Load at Week 12Time frame: Baseline, Week 12
- Change From Baseline in Alanine Aminotransferase (ALT) at Week 12Time frame: Baseline, Week 12
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bakersfield, California
Novartis Investigative Site
Lancaster, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Arlington, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Newport News, Virginia
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Clichy, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.